Solstice Advanced Materials heads into its August 5 earnings report with a notable divergence: the stock is up on the week, but bears have been quietly rebuilding positions through a month where the share price has lost nearly a quarter of its value.
The most important short-side development is not the current level but the velocity of change. Short interest climbed 40% over the past month, reaching 3.5% of the free float — a level that still sits below the threshold of genuine concern but is moving in a direction worth tracking. The step-change came in late June, when short shares jumped from roughly 4 million to 5.6 million and held there. Borrow cost, though still cheap at 0.40%, has risen 32% over the past week — a modest absolute number that nonetheless reflects fresh demand for borrowed stock. Crucially, the lending pool remains extremely deep. Availability is now at roughly 3,600% — meaning there are more than 36 shares available to borrow for every one currently borrowed — so there is no squeeze dynamic here. The short thesis, such as it is, faces no structural friction in the borrow market.
Options positioning adds a layer of caution without flashing a full alarm. The put/call ratio has eased to 1.06, sitting modestly above its 20-day average of 0.86, and the z-score of 0.42 puts it well within normal range. What's notable is the directional shift: through most of late June, the PCR was running below 0.31, touching its near-52-week low. It then jumped sharply into mid-range territory around July 7 before settling back. The current reading reflects more balanced options activity than the call-heavy skew that characterised late June. The 52-week put/call range stretches from 0.27 to 4.78, so current positioning is mild. The ORTEX short score has also been drifting lower all week, moving from 37.5 on July 7 down to 34.2 today — suggesting the aggregate signal on short-side conviction is actually softening even as raw share counts stay elevated.
The price story is the most striking contrast. SOLS is down 24% over the past month to $63.36, yet has recovered 2% on the week and gained nearly 4% on Tuesday alone. That one-day jump followed last week's Q2 earnings beat, which impressed on revenue and margin. Close US peer ESI gained 5.4% over the same week and CC fell 1.2%, suggesting SOLS is broadly keeping up with the better end of its specialty chemicals peer group after its sharp dip. The valuation data is flagged as stale (21 days old against a 14-day threshold), but at last reading the stock traded near 30x trailing earnings and roughly 14.8x EV/EBITDA — multiples that hold up if management's commentary on semiconductor and aerospace demand proves durable.
Institutional positioning offers a mild positive lean. BlackRock added nearly 936,000 shares through June 30, lifting its stake to 9.4% of the company — the largest holder by some margin. Alkeon Capital and XN LP also built material new positions in Q1. The insider side is less informative: recent activity consists of routine equity award grants paired with small sell-to-cover transactions by the Chief Accounting Officer and HR Director, each rated at minimum significance. There is no discretionary purchase or outsized sale from senior management.
With the next earnings event set for August 5, what to watch is whether the short interest build of the past month continues to accelerate, or stalls now that the Q2 result has partially reset sentiment — and whether the options PCR, currently drifting back from its July 7 spike, resolves toward the calm levels of late June or firms up again as the next print approaches.
See the live data behind this article on ORTEX.
Open SOLS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
